Xarelto [SPAF-QOL] Post-marketing Surveillance in Japan

Treatment Satisfaction Under Rivaroxaban (ACTS/TSQM)

The objective of this study is to understand if Rivaroxaban can improve treatment satisfaction of Warfarin patients and assess the safety and effectiveness of Xarelto in real clinical practice.

A total of 725 patients are to be enrolled and followed for a 6 months.period. QOL survey will be conducted at month 0, 3, 6 using ACTS/TSQM.

This study is categorized as a regulatory post-marketing surveillance in Japan, and it is a local prospective and observational study of patients who have received Xarelto for SPAF.

Inclusion Criteria:

• Patients treated by Warfarin for their atrial fibrillation for at least two months at the time of the study initiation.
• Rivaroxaban naïve patients
• Patients 20 years old or older.
• Patients who agree to sign the inform consent

Exclusion Criteria:

• Patients who are contraindicated by product label